Quick Brief

Nature reported this science story on July 3, 2026. Neoadjuvant therapy (NAT) is an important treatment strategy in surgical oncology, but not all patients benefit equally from it. This systematic review is the first to evaluate artificial intelligence (AI) models predicting NAT response from hematoxylin and eosin (H&E)-stained biopsies slides of solid tumors. A systematic search across five databases was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Out of 235 studies, 25 met the inclusion criteria and were analyzed regarding their AI methodologies, data modalities, and type of NAT. Most studies reported area under the curve (AUC) ranging from 0.70 to 0.90, and approximately 40% included external validation cohorts. In conclusion, AI models show promise in predicting NAT response from pathological slides, but future work should emphasize standardized data acquisition, patient-level validation, data transparency, and code sharing.

This brief is based on the stored source metadata available to BRIEFXIFY at publication time. When the original feed provides limited body text, the summary stays close to the verified headline, source, category, and description instead of adding unsupported detail.

Why This Matters

The story matters because it belongs to the science feed and may affect readers following updates from Nature. The available details help readers quickly understand the subject and decide whether to open the original report for full context.

Background

News feeds often provide a headline, short description, image, source name, and publication time rather than the complete article body. BRIEFXIFY uses those fields to create a concise overview while keeping the original source linked for readers who need the full report.

Key Details

  • Category: science
  • Source: Nature
  • Published: July 3, 2026
  • Available source detail: Neoadjuvant therapy (NAT) is an important treatment strategy in surgical oncology, but not all patients benefit equally from it. This systematic review is the first to evaluate artificial intelligence (AI) models predicting NAT response from hematoxylin and eosin (H&E)-stained biopsies slides of solid tumors. A systematic search across five databases was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Out of 235 studies, 25 met the inclusion criteria and were analyzed regarding their AI methodologies, data modalities, and type of NAT. Most studies reported area under the curve (AUC) ranging from 0.70 to 0.90, and approximately 40% included external validation cohorts. In conclusion, AI models show promise in predicting NAT response from pathological slides, but future work should emphasize standardized data acquisition, patient-level validation, data transparency, and code sharing.
  • The original report is linked on the article page.

Possible Impact

The likely impact depends on the full facts in the original report. Based on the available metadata, this item is most relevant to readers tracking the topic, the named source, and related developments in the same category.

What To Watch Next

Readers should watch for follow-up reporting, official updates, and additional context from the original publisher or other reliable sources. If the source updates the article, the original link remains the best place for complete details.

Source and Transparency

Source: Nature

This BRIEFXIFY brief is AI-assisted and based on publicly available news source information. It is written for quick understanding and does not replace the original report. Read the original source for full context.